People with multiple sclerosis can show signs of something wrong five years before the onset of disease, much earlier than previously thought, according to a new analysis of health records from people with the condition. The new research, published today in Lancet Neurology, is a first step to identifying red flags to help doctors screen for the disease and start…
Jay Ingram is the former co-host of CBC One’s Quirks and Quarks, as well as the Discovery Channel’s Daily Planet. He is also the author of over a dozen science books, including most recently, “The Science of Why”, as well as co-founder of the interactive science event, Beakerhead. Science in the City sat down with Jay to discuss Beakerhead, its…
A drug created from a malaria protein stopped tumour growth of chemotherapy-resistant bladder cancer, offering hope for cancer patients not responding to standard treatments. “This is the first study where we put the concept of using malaria proteins for cancer therapy into a direct clinical context,” said Mads Daugaard, an assistant professor of urologic science at the University of British…
Last week, I received an email from my PhD alma mater UBC and instead of a request for donations or an invitation to an event with the expectation of soliciting a donation later, I was treated to a new dataset emerging from the west coast. UBC has collated responses from its PhD graduates between 2005 and 2013 (myself included!) into…
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced a proposed registered public offering of its common stock and warrants to purchase common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering…
An early report on the molecular subtyping of muscle-invasive bladder cancer (MIBC) by gene expression suggested that response to neoadjuvant chemotherapy (NAC) varies by subtype. To investigate the ability of molecular subtypes to predict pathological downstaging and survival after NAC. Whole transcriptome profiling was performed on pre-NAC transurethral resection specimens from 343 patients with MIBC. Samples were classified according to four published…
Researchers have obtained an unprecedented view of the ‘ballistic’ weaponry of planktonic microbes, including one that can fire projectiles as if wielding a Gatling gun. “We think of plankton as the tiny alphabet soup of the ocean, floating around passively while larger organisms eat it,” says biologist Gregory Gavelis, who lead the study while a researcher at the University of…
Hundreds of people are expected to march in Vancouver this Saturday to celebrate the role of science in our lives and support evidence-based government policy. Communications officer Kristina Charania says the idea for the march started in January in response to U.S. President Donald Trump’s administration deleting nearly all mentions of climate change off the White House website. Climate change received fairly high…
Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced that it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) and a preliminary prospectus with the securities regulatory authorities in each…
Success is such an arbitrary measure. “My main advice is to create your own definition of success”, recommends Grace Lee, a transition expert. “Very often we let everyone else define what it means to be successful: a great career, a family… In our field, articles became the currency of success, but that is not what defines you”. Grace metamorphosed a…
